Antithrombin prevents stress-induced gastric mucosal injury by increasing the gastric prostacyclin level in rats.
The interaction of antithrombin (AT) with cell surface glycosaminoglycans has been shown to promote the endothelial release of prostacyclin (PGI2). Because PGI2 plays an important role in gastric cytoprotection, we examined whether AT prevents water-immersion restraint stress (WIR)-induced gastric mucosal injury in rats by promoting the endothelial release of PGI2. Intravenous administration of AT (250 U/kg) prevented WIR-induced gastric mucosal injury in rats. Gastric levels of 6-keto-prostaglandin F1alpha, a stable metabolite of PGI2, were significantly increased 0.5 and 1 hour after WIR in animals administered AT compared with control animals. The effects induced by AT in animals subjected to WIR were not observed in animals that were administered DEGR-Xa, a selective inhibitor of thrombin generation, or Trp49-modified AT, which lacks affinity for heparin. In animals subjected to WIR gastric mucosal blood flow was significantly reduced with a simultaneous increase in gastric mucosal microvascular permeability. Activated neutrophils have been implicated in the WIR-induced reduction of gastric mucosal blood flow by increasing microvascular permeability. Although AT prevented the reduction of gastric mucosal blood flow and the increase in gastric mucosal microvascular permeability in animals subjected to WIR, neither DEGR-Xa nor Trp49-modified AT had any effect. Pretreatment of animals with indomethacin completely inhibited the protective effects of AT against WIR-induced gastric mucosal injury and the AT-induced increase in post-WIR gastric 6-keto-prostaglandin F1alpha levels. These results strongly suggest that AT prevents stress-induced gastric mucosal injury by increasing the gastric levels of PGI2 through the interaction of AT with cell-surface glycosaminoglycans, thus increasing gastric mucosal blood flow both by vasodilation and by inhibiting neutrophil activation.
Isobe
H
H
Department of Laboratory Medicine, Kumamoto University School of Medicine, Japan.
Okajima
K
K
Liu
W
W
Harada
N
N
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000418:Albumins / Q000378:metabolism; D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000991:Antithrombins / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D011464:Epoprostenol / Q000378:metabolism*; D015951:Factor Xa / Q000494:pharmacology; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005753:Gastric Mucosa / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D007101:Immersion; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow; D013276:Stomach Ulcer / Q000097:blood / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D013312:Stress, Physiological / Q000150:complications*; D013997:Time Factors; D014364:Tryptophan / Q000737:chemistry
D000418:Albumins; D000590:Amino Acid Chloromethyl Ketones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000991:Antithrombins; C097736:dansyl-glutamyl-glycyl-arginyl chloromethyl ketone-treated factor Xa; D015121:6-Ketoprostaglandin F1 alpha; D014364:Tryptophan; D005337:Fibrin; D005340:Fibrinogen; D011464:Epoprostenol; D009195:Peroxidase; D015951:Factor Xa; D007213:Indomethacin